GGrantIndex
Sort

82,697 grants matching vaccine development

Identification of human tumor-associated antigens

$788,196
Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA

Maturation of human humoral immunity through repeat malaria challenges

$788,047
Kim C Williamson · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2024 · AI

MAb Passive Vaccination against Acinetobacter baumannii

$788,017
Brad J Spellberg · University Of Southern California · R01 · FY2023 · AI

Protective immunity to typhoid

$787,940
Stephen J McSorley · University Of Connecticut Sch Of Med/Dnt · P01 · FY2015 · AI

Application of a syndemic framework to HPV and HSV infection in emergent adult men

$787,932
Danielle C Ompad · New York University · R01 · FY2017 · AI

Task A05: Small animal models for cytomegalovirus and herpes simplex viruses

$787,888
David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2022 · AI

ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1

$787,723
Scripps Research Institute · R01 · FY2005 · AI

Hydrogel-based lymphoid tissues for generation of activated human B cells and delivery in vivo

$787,654
Ankur Singh · Georgia Institute Of Technology · R01 · FY2024 · AI

Immune diagnostics and vaccine targets: breast cancer antigens from mice to women

$787,633
Mary L. Disis · University Of Washington · U01 · FY2009 · CA

Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

$787,601
Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Translation of a highly protective tularemia vaccine to the NHP model

$787,600
Karsten R.o. Hazlett · Albany Medical College · R01 · FY2025 · AI

CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS

$787,556
Walter A. Orenstein · Emory University · N01 · FY2018 · AI

Clinical Center in COPD

$787,550
University Of Alabama At Birmingham · U10 · FY2003 · HL

Human Intestinal Mucosal Immune and Functional Response to S. typhi

$787,549
Alessio Fasano · University Of Maryland Baltimore · U19 · FY2015 · AI

Assembly of MHC Class I Molecules in Vitro and in Vivo

$787,431
Hidde L Ploegh · Whitehead Institute For Biomedical Res · R01 · FY2009 · AI

Development of a Self Inactivating, Highly Effective TB Vaccine

$787,367
Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI

TASK V13: DEEP ANTIBODY PROFILING FOR RSV INFECTION AND VACCINATION

$787,348
Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2022 · AI

Pediatric immune set points

$787,338
John S Tsang · Yale University · P01 · FY2025 · AI

Understanding DOCK8 Function in Health and Human Disease

$787,338
Helen Su · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

DEFINING THE INFANT IMMUNE RESPONSE TO HIV

$787,267
Julie M Overbaugh · Fred Hutchinson Cancer Research Center · R01 · FY2016 · AI

Development of Efficacious and Stable Nasal Vaccine Formulations

$787,200
Herman F. Staats · Duke University · U01 · FY2012 · AI

CMV Subunit Vaccine in Young Women at Risk

$787,173
Robert Floyd Pass · University Of Alabama At Birmingham · U01 · FY2008 · AI

Chemoprophylaxis and HIV Host Interactions

$787,145
Robert M. Grant · J. David Gladstone Institutes · R01 · FY2006 · AI

Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines

$787,127
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Clinical trials employing cancer vaccine combination therapies

$787,127
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA